This study is for adults with advanced small cell lung cancer who can receive standard treatments like chemotherapy and immunotherapy. The goal is to test how well different doses of a new medicine, BI 764532, are tolerated when given with standard treatments. BI 764532 is designed to help the immune system fight cancer. Participants will receive this medicine and standard treatments through a needle in a vein.
To join, you need to be 18 or older, have a specific type of lung cancer, and not have received certain previous cancer treatments. Participants will have regular visits to the study site where doctors will check their health and perform tests.
- Study Length: Duration depends on treatment response; visits are regular.
- Participation: Includes receiving medicines and regular health checks.
- Eligibility: Adults with a specific lung cancer type, no prior systemic treatment for this cancer, and meet other health criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand